Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with high unmet medical needs, leveraging expertise across multiple vaccine modalities to deliver first-, best-, or only-in-class solutions. The company generates revenue from three marketed travel vaccines—IXIARO/JESPECT for Japanese encephalitis, DUKORAL for cholera and enterotoxigenic E. coli, and IXCHIQ for chikungunya—which are sold directly to end markets and through its commercial infrastructure. Revenue from these established products funds advancement of a clinical pipeline including VLA15 (a Lyme disease vaccine in partnership with Pfizer), S4V2 (a tetravalent Shigella vaccine), and VLA1601 (a Zika vaccine), while the company also operates three manufacturing facilities across Europe and pursues selective partnerships to leverage large-pharma capabilities.